Nextbiotix Exeliom Biosciences

Feb 15, 2019

Nextbiotix becomes Exeliom Biosciences

#funding #SeriesA #Clinicaltrials

Jun 30, 2023

Exeliom Biosciences Announces Series A Extension and Final Closing with Total of €24 Million ($26 Million) to Progress the Clinical Development of its Lead Candidate in Immuno-Oncology and Infectious Diseases.

Clinical Trial Live Biotherapeutics Crohn's Disease Belgium

Feb 24, 2022

Exeliom Biosciences announces approval of Clinical Trial Application from the Belgian Agency for Single Strain Live Biotherapeutic EXL01 (Faecalibacterium prausnitzii) for the treatment of Crohn’s Disease

Mar 4, 2024

Exeliom is awarded a $500k grant from the Crohn's and Colitis Foundation!

contact

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.